Regulatory Reclassification Sparks Renewed Interest in Medical Cannabis Investment
On April 23, 2024, the U.S. Department of Justice issued an order that moves certain FDA‑approved marijuana products and state‑licensed medical‑cannabis items into Schedule III of the Controlled Substances Act. Signed by Acting Attorney General Todd Blanche, the directive is already reshaping the investment landscape, prompting venture funds to re‑engage and encouraging drug developers to explore private financings and potential public listings, according to industry coverage by Hoodline.
The shift is viewed by stakeholders as a pragmatic step toward enabling U.S.–based clinical trials, easing banking constraints, and laying groundwork for future initial public offerings (IPOs). Importantly, the order does not federally legalize recreational or medical cannabis; adult‑use products remain classified under Schedule I, preserving a dual‑regulatory environment for companies that operate in both markets.
What the Order Actually Does
The Justice Department’s directive specifically places:
- FDA‑approved cannabis‑derived medicines, and
- Products sold under qualifying state medical‑marijuana licenses
- into Schedule III.
It also launches an expedited review to assess broader rescheduling of the plant. Officials say the move balances the need for rigorous federal oversight with the desire to advance legitimate medical research.
Legal analysis from Holland & Knight highlights three immediate operational effects:
- State licensees must now obtain new DEA registrations to handle Schedule III substances.
- The IRS is directed to consider retrospective relief from Internal Revenue Code Section 280E for qualified operators, potentially allowing deductions of ordinary business expenses.
- The DEA is instructed to fast‑track registration applications, reducing administrative lag.
While these changes alleviate long‑standing barriers, Holland & Knight cautions that major card networks and many banks are likely to proceed cautiously until clearer guidance emerges.
Corporate Financing and Emerging IPO Prospects
The regulatory shift has already triggered concrete fundraising activity.
- Ananda Pharma is preparing a private raise of US$10 million to US$20 million over the next few months, according to Reuters.
- IGC Pharma, which is developing a low‑dose THC liquid for agitation in Alzheimer’s patients, is evaluating a US$50 million funding round later in 2024.
- Executives from Avicanna and BRC Therapeutics have told investors that the federal reclassification eases reputational hurdles and could open pathways to IPOs on major exchanges for firms running tightly regulated drug programs.
BRC Therapeutics CEO George Hodgin described the rescheduling as a “watershed moment,” noting that it has attracted renewed attention to the company’s clinical pipelines.
These developments contrast sharply with the historical scarcity of FDA‑cleared cannabis medicines. To date, Epidiolex—a cannabidiol‑based treatment for certain epilepsies—remains the sole cannabis‑derived product approved by the FDA, a fact reflected in its label and frequently cited by analysts as a benchmark for therapeutic legitimacy.
Operational and Legal Facilitation
Beyond capital access, the Schedule III placement promises to ease several day‑to‑day challenges for medically licensed operators:
- Improved eligibility for traditional deposit accounts and merchant services.
- Ability to deduct standard business costs, which was previously hampered by Section 280E’s prohibition on expense deductions for Schedule I substances.
Nevertheless, the DOJ order stops short of full federal legalization. Adult‑use cannabis continues to sit in Schedule I, meaning businesses that straddle medical and recreational lines must still navigate a fragmented regulatory map.
Outlook: Upcoming DEA Hearing and Market Watch
Industry participants are closely monitoring an accelerated DEA hearing slated to begin on June 29, 2024, which will examine the possibility of broader marijuana rescheduling. The outcome of that proceeding, together with forthcoming IRS guidance on Section 280E relief, is expected to influence deal structures, cash‑flow modeling, and the timing of potential IPOs.
For founders and investors, the current window represents a meaningful—though still narrow—reopening of the market, particularly for companies whose programs align closely with FDA standards and state medical frameworks. While operational, tax, and state‑law complexities persist, the focus remains on tracking fundraising announcements from biotech firms and awaiting the regulatory signals that will emerge from the June hearing.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid‑derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
Source: Here
